Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 40

1.

Multi-clade H5N1 virus-like particles: Immunogenicity and protection against H5N1 virus and effects of beta-propiolactone.

Pushko P, Tretyakova I, Hidajat R, Sun X, Belser JA, Tumpey TM.

Vaccine. 2018 Jul 5;36(29):4346-4353. doi: 10.1016/j.vaccine.2018.05.092. Epub 2018 Jun 7.

2.

Virus-like particles displaying H5, H7, H9 hemagglutinins and N1 neuraminidase elicit protective immunity to heterologous avian influenza viruses in chickens.

Pushko P, Tretyakova I, Hidajat R, Zsak A, Chrzastek K, Tumpey TM, Kapczynski DR.

Virology. 2017 Jan 15;501:176-182. doi: 10.1016/j.virol.2016.12.001. Epub 2016 Dec 6.

3.

Mono- and quadri-subtype virus-like particles (VLPs) containing H10 subtype elicit protective immunity to H10 influenza in a ferret challenge model.

Pushko P, Sun X, Tretyakova I, Hidajat R, Pulit-Penaloza JA, Belser JA, Maines TR, Tumpey TM.

Vaccine. 2016 Oct 17;34(44):5235-5242. doi: 10.1016/j.vaccine.2016.09.012. Epub 2016 Sep 20.

4.

Vaccination with virus-like particles containing H5 antigens from three H5N1 clades protects chickens from H5N1 and H5N8 influenza viruses.

Kapczynski DR, Tumpey TM, Hidajat R, Zsak A, Chrzastek K, Tretyakova I, Pushko P.

Vaccine. 2016 Mar 18;34(13):1575-1581. doi: 10.1016/j.vaccine.2016.02.011. Epub 2016 Feb 8.

5.

Next generation sequencing of DNA-launched Chikungunya vaccine virus.

Hidajat R, Nickols B, Forrester N, Tretyakova I, Weaver S, Pushko P.

Virology. 2016 Mar;490:83-90. doi: 10.1016/j.virol.2016.01.009. Epub 2016 Feb 6.

6.

Preparation of quadri-subtype influenza virus-like particles using bovine immunodeficiency virus gag protein.

Tretyakova I, Hidajat R, Hamilton G, Horn N, Nickols B, Prather RO, Tumpey TM, Pushko P.

Virology. 2016 Jan;487:163-71. doi: 10.1016/j.virol.2015.10.007. Epub 2015 Nov 2.

7.

Recombinant H7 hemagglutinin forms subviral particles that protect mice and ferrets from challenge with H7N9 influenza virus.

Pushko P, Pujanauski LM, Sun X, Pearce M, Hidajat R, Kort T, Schwartzman LM, Tretyakova I, Chunqing L, Taubenberger JK, Tumpey TM.

Vaccine. 2015 Sep 11;33(38):4975-82. doi: 10.1016/j.vaccine.2015.07.026. Epub 2015 Jul 21.

8.

Plasmid DNA initiates replication of yellow fever vaccine in vitro and elicits virus-specific immune response in mice.

Tretyakova I, Nickols B, Hidajat R, Jokinen J, Lukashevich IS, Pushko P.

Virology. 2014 Nov;468-470:28-35. doi: 10.1016/j.virol.2014.07.050. Epub 2014 Aug 16.

9.

Targeting the vaginal mucosa with human papillomavirus pseudovirion vaccines delivering simian immunodeficiency virus DNA.

Gordon SN, Kines RC, Kutsyna G, Ma ZM, Hryniewicz A, Roberts JN, Fenizia C, Hidajat R, Brocca-Cofano E, Cuburu N, Buck CB, Bernardo ML, Robert-Guroff M, Miller CJ, Graham BS, Lowy DR, Schiller JT, Franchini G.

J Immunol. 2012 Jan 15;188(2):714-23. doi: 10.4049/jimmunol.1101404. Epub 2011 Dec 14.

10.

Vaccine-elicited SIV and HIV envelope-specific IgA and IgG memory B cells in rhesus macaque peripheral blood correlate with functional antibody responses and reduced viremia.

Brocca-Cofano E, McKinnon K, Demberg T, Venzon D, Hidajat R, Xiao P, Daltabuit-Test M, Patterson LJ, Robert-Guroff M.

Vaccine. 2011 Apr 12;29(17):3310-9. doi: 10.1016/j.vaccine.2011.02.066. Epub 2011 Mar 5.

11.

Multiple vaccine-elicited nonneutralizing antienvelope antibody activities contribute to protective efficacy by reducing both acute and chronic viremia following simian/human immunodeficiency virus SHIV89.6P challenge in rhesus macaques.

Xiao P, Zhao J, Patterson LJ, Brocca-Cofano E, Venzon D, Kozlowski PA, Hidajat R, Demberg T, Robert-Guroff M.

J Virol. 2010 Jul;84(14):7161-73. doi: 10.1128/JVI.00410-10. Epub 2010 May 5.

12.

Construction and immunogenicity of replication-competent adenovirus 5 host range mutant recombinants expressing HIV-1 gp160 of SF162 and TV1 strains.

Hidajat R, Kuate S, Venzon D, Kalyanaraman V, Kalisz I, Treece J, Lian Y, Barnett SW, Robert-Guroff M.

Vaccine. 2010 May 21;28(23):3963-71. doi: 10.1016/j.vaccine.2010.03.046. Epub 2010 Apr 9.

13.

Correlation of vaccine-elicited systemic and mucosal nonneutralizing antibody activities with reduced acute viremia following intrarectal simian immunodeficiency virus SIVmac251 challenge of rhesus macaques.

Hidajat R, Xiao P, Zhou Q, Venzon D, Summers LE, Kalyanaraman VS, Montefiori DC, Robert-Guroff M.

J Virol. 2009 Jan;83(2):791-801. doi: 10.1128/JVI.01672-08. Epub 2008 Oct 29.

14.

Comparative evaluation of oral and intranasal priming with replication-competent adenovirus 5 host range mutant (Ad5hr)-simian immunodeficiency virus (SIV) recombinant vaccines on immunogenicity and protective efficacy against SIV(mac251).

Zhou Q, Hidajat R, Peng B, Venzon D, Aldrich MK, Richardson E, Lee EM, Kalyanaraman VS, Grimes G, Gómez-Román VR, Summers LE, Malkevich N, Robert-Guroff M.

Vaccine. 2007 Nov 19;25(47):8021-35. Epub 2007 Sep 29.

PMID:
17935840
15.

The value of VEP in the diagnosis and post-operative monitoring of meningioma.

Hidajat RR, McLay JL, Goode DH, Hidayat JR.

Doc Ophthalmol. 2006 Nov;113(3):165-9. Epub 2006 Oct 4.

PMID:
17019611
16.

New Zealand experience of I125 brachytherapy for choroidal melanoma.

Stack R, Elder M, Abdelaal A, Hidajat R, Clemett R.

Clin Exp Ophthalmol. 2005 Oct;33(5):490-4.

PMID:
16181274
17.
18.

Hepatitis C virus NS3 protein interacts with ELKS-{delta} and ELKS-{alpha}, members of a novel protein family involved in intracellular transport and secretory pathways.

Hidajat R, Nagano-Fujii M, Deng L, Tanaka M, Takigawa Y, Kitazawa S, Hotta H.

J Gen Virol. 2005 Aug;86(Pt 8):2197-208.

PMID:
16033967
19.

EOG as a monitor of desferrioxamine retinal toxicity.

Hidajat RR, McLay JL, Goode DH, Spearing RL.

Doc Ophthalmol. 2004 Nov;109(3):273-8.

PMID:
15957612
20.

A fast system for reporting the Farnsworth-Munsell 100-hue colour vision test.

Hidajat RR, Hidayat JR, McLay JL, Elder MJ, Goode DH, Pointon RC.

Doc Ophthalmol. 2004 Sep;109(2):109-14.

PMID:
15881255
21.

Suppression of hepatitis C virus replicon by RNA interference directed against the NS3 and NS5B regions of the viral genome.

Takigawa Y, Nagano-Fujii M, Deng L, Hidajat R, Tanaka M, Mizuta H, Hotta H.

Microbiol Immunol. 2004;48(8):591-8.

22.

Influence of axial length of normal eyes on PERG.

Hidajat R, Mclay J, Burley C, Elder M, Morton J, Goode D.

Doc Ophthalmol. 2003 Sep;107(2):195-200.

PMID:
14661910
23.

Hepatitis C virus core protein selectively inhibits synthesis and accumulation of p21/Waf1 and certain nuclear proteins.

Oka K, Nagano-Fujii M, Yoshida I, Hidajat R, Deng L, Akutsu M, Hotta H.

Microbiol Immunol. 2003;47(6):429-38.

24.

A comparison of two patient-friendly ERG electrodes.

Hidajat RR, McLay JL, Elder MJ, Goode DH, Morton JP, Burley CD.

Australas Phys Eng Sci Med. 2003 Mar;26(1):30-4.

PMID:
12854623
25.
26.

Normalisation of visual evoked potentials after optic neuritis.

Hidajat RR, Goode DH.

Doc Ophthalmol. 2003 May;106(3):305-9.

PMID:
12737508
27.

Inhibition of protein synthesis by the nonstructural proteins NS4A and NS4B of hepatitis C virus.

Florese RH, Nagano-Fujii M, Iwanaga Y, Hidajat R, Hotta H.

Virus Res. 2002 Dec;90(1-2):119-31.

PMID:
12457968
28.

Physical interaction between hepatitis C virus NS4B protein and CREB-RP/ATF6beta.

Tong WY, Nagano-Fujii M, Hidajat R, Deng L, Takigawa Y, Hotta H.

Biochem Biophys Res Commun. 2002 Dec 6;299(3):366-72.

PMID:
12445808
29.

The clinical value of ophthalmic electrodiagnosis in children.

Hidajat RR, Goode DH.

Australas Phys Eng Sci Med. 2001 Sep;24(3):172-6.

PMID:
11764400
30.

Inhibition of p21/Waf1/Cip1/Sdi1 expression by hepatitis C virus core protein.

Yoshida I, Oka K, Hidajat R, Nagano-Fujii M, Ishido S, Hotta H.

Microbiol Immunol. 2001;45(10):689-97.

31.

Pattern VEP for glare sensitivity testing.

Hidajat RR, Goode DH.

Australas Phys Eng Sci Med. 2000 Jun;23(2):52-6.

PMID:
10979594
32.

Acute ocular methanol toxicity: clinical and electrophysiological features.

McKellar MJ, Hidajat RR, Elder MJ.

Aust N Z J Ophthalmol. 1997 Aug;25(3):225-30. Review.

PMID:
9296298
33.

Primer-directed mutagenesis of an intact plasmid by using Pwo DNA polymerase in long distance inverse PCR.

Hidajat R, McNicol P.

Biotechniques. 1997 Jan;22(1):32-4. No abstract available.

35.

Serum and neutrophils alter the rate of excretory/secretory antigen release by Toxocara canis infective larvae in vitro.

Williamson HJ, Allardyce RA, Clemett RS, Hidajat RR.

Parasite Immunol. 1990 Mar;12(2):175-87.

PMID:
2320380
36.

Ocular Toxocara canis infections: diagnosis by enzyme immunoassay.

Clemett RS, Williamson HJ, Hidajat RR, Allardyce RA, Stewart AC.

Aust N Z J Ophthalmol. 1987 May;15(2):145-50.

PMID:
3620188
37.

The relationship between toxocara ELISA absorbance values and toxocara ELISA titres: a comparative study.

Clemett RS, Hidajat RR, Allardyce RA, Stewart AC.

Aust N Z J Ophthalmol. 1986 Aug;14(3):199-203.

PMID:
3768173
38.

Retinopathy of prematurity: review of a five-year period, examination techniques and recommendations for screening.

Clemett RS, Darlow BA, Hidajat RR, Tarr KH.

Aust N Z J Ophthalmol. 1986 May;14(2):121-5.

PMID:
3801204
39.

Toxocaral infection in hydatid control officers: diagnosis by enzyme immunoassay.

Clemett RS, Hidajat RR, Allardyce RA, Stewart AC.

N Z Med J. 1985 Sep 11;98(786):737-9.

PMID:
3863049
40.

The visual-evoked cortical potential to colour stimuli in multiple sclerosis and optic neuritis.

Tarr KH, Hidajat RR, Goode DH.

Trans Ophthalmol Soc N Z. 1984;36:13-5. No abstract available.

PMID:
6591605

Supplemental Content

Loading ...
Support Center